

Amendments to the Claims:

Please cancel Claims 34, 36, 46 and 48 without prejudice to or disclaimer of the subject matter recited therein.

Please amend Claims 16, 17, 33, 35, 37-40, 44, 45, 47 and 49 as follows.

Claims 1-15 (Canceled)

16. (Currently Amended) A method of stimulating the immune system of a human to produce an HIV-1 immune response, comprising administering to the human the combination of:

a) at least one peptide that comprises at least nine consecutive amino acid residues of the sequence Xaa₁ Xaa₂ Xaa₃ Xaa₄ Xaa₅ Xaa₆ Ala Xaa₈ Xaa₉ Gln Thr Pro Trp Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Xaa₁₈ Val Xaa₂₀ (SEQ ID NO. 1),

wherein Xaa in position 1 is Lys or Arg,

Xaa in position 2 is Ala, Gly, Ser or Arg,

Xaa in position 3 is Leu or Met,

Xaa in position 4 is Gly or Arg,

Xaa in position 5 is Pro, Thr, Val, Ser, Gln or Ala,

Xaa in position 6 is Gly, Ala, Lys, Arg, Gln or Glu,

Xaa in position 8 is Thr or Ser,

Xaa in position 9 is Leu or Ile,

Xaa in position 14 is Thr, Ser or Val,

Xaa in position 15 is Ala or Ser,

Xaa in position 16 is Cys or Ser,

Xaa in position 17 is Gln or Leu,

Xaa in position 18 is Gly, Glu or Arg, and

Xaa in position 20 is Gly or Arg;

b) at least one peptide that comprises at least six consecutive amino acid residues of the sequence Xaa₁ Xaa₂ Xaa₃ Xaa₄ Xaa₅ Gly Leu Asn Pro Leu Val [Gly]_n Xaa₁₂ Xaa₁₃ Tyr Xaa₁₅ Pro Xaa₁₇ Xaa₁₈ Ile Leu Xaa₂₁ Xaa₂₂ (SEQ ID NO. 4),

wherein Xaa in position 1 is Arg, Lys, Asp or none,

Xaa in position 2 is Trp, Gly, Lys or Arg,

Xaa in position 3 is Ile, Leu, Val or Met,

Xaa in position 4 is Ile, Val or Leu,

Xaa in position 5 is Leu, Met, Val or Pro,

Xaa in position 12 is Arg or Lys,

Xaa in position 13 is Met or Leu,

Xaa in position 15 is Ser, Cys or Gln,

Xaa in position 17 is Thr, Val, Ile, Ser or Ala,

Xaa in position 18 is Ser, Gly or Thr,

Xaa in position 21 is Asp, Glu, Cys or Gly, and

Xaa in position 22 is Gly or none,

and wherein n = 0, 1, 2 or 3;

c) at least one peptide that comprises at least six consecutive amino acid residues of the sequence Xaa₁ Xaa₂ Xaa₃ Pro Ile Pro Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂

[Gly]_n Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Xaa₁₈ Xaa₁₉ Xaa₂₀ Xaa₂₁ Xaa₂₂ Xaa₂₃ Xaa₂₄ (SEQ ID NO. 9),

wherein Xaa in position 1 is Asn, Ser, Gly, His, Ala, Pro, Arg or none,

Xaa in position 2 is Asn, Ala or Lys,

Xaa in position 3 is Pro, Gln, Gly, Ile or Leu,

Xaa in position 7 is Val or Ala,

Xaa in position 8 is Gly or Lys,

Xaa in position 9 is Glu, Asp, Lys, Phe or Thr,

Xaa in position 10 is Ile, Met, Val or Leu,

Xaa in position 11 is Tyr, Leu or none,

Xaa in position 12 is Ser or none,

Xaa in position 13 is Arg or none,

Xaa in position 14 is Asp, Arg, Trp, Ala or none,

Xaa in position 15 is Ile or none,

Xaa in position 16 is Tyr or none,

Xaa in position 17 is Lys or Arg,

Xaa in position 18 is Arg, Lys or Asp,

Xaa in position 19 is Trp or Gly,

Xaa in position 20 is Ile, Met, Val, Gln or Ala,

Xaa in position 21 is Ile, Val or Ala,

Xaa in position 22 is Leu, Met or Val,

Xaa in position 23 is Gly or Cys, and

Xaa in position 24 is Leu or none, and

wherein n = 1, 2 or 3; and

d) at least one peptide selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 that comprises at least six consecutive amino acid residues of the sequence ~~Xaa₁Xaa₂Ile Ile Xaa₅Xaa₆Xaa₇Xaa₈Xaa₉Leu Xaa₁₁[Gly]_n[Arg]_mXaa₁₂Xaa₁₃Xaa₁₄Xaa₁₅Xaa₁₆Xaa₁₇Xaa₁₈Xaa₁₉Xaa₂₀Xaa₂₁Xaa₂₂Xaa₂₃Xaa₂₄Xaa₂₅(SEQ ID NO: 15)~~

~~wherein Xaa in position 1 is Pro, Lys, Arg or none;~~

~~Xaa in position 2 is Glu, Arg, Phe or Lys;~~

~~Xaa in position 5 is Pro or Thr;~~

~~Xaa in position 6 is Met, Thr or Nle;~~

~~Xaa in position 7 is Phe or Leu;~~

~~Xaa in position 8 is Ser, Thr, Ala or Met;~~

~~Xaa in position 9 is Ala, Glu or Leu;~~

~~Xaa in position 11 is Ser or none;~~

~~Xaa in position 12, is Ala, Arg or none;~~

~~Xaa in position 13 is Ile, Leu or none;~~

~~Xaa in position 14 is Ser, Ala, Leu or none;~~

~~Xaa in position 15 is Tyr, Glu or Asp;~~

~~Xaa in position 16 is Gly or Asp;~~

~~Xaa in position 17 is Ala or Leu;~~

~~Xaa in position 18 is Thr, Ile, Val, Leu or Asn;~~

~~Xaa in position 19 is Pro, Thr or Ser;~~

~~Xaa in position 20 is Tyr, Phe, Nle, His or Gln;~~

~~_____ Xaa in position 21 is Asp, Asn, Leu or Ala;~~
~~_____ Xaa in position 22 is Leu, Ile, Val or Asn;~~
~~_____ Xaa in position 23 is Asn, Tyr, Cys or Gly;~~
~~_____ Xaa in position 24 is Thr, Met, Ile, Ala, Val or none, and~~
~~_____ Xaa in position 25 is Gly or none, and~~
~~_____ wherein n = 1, 2 or 3, and m = 0, 1, 2 or 3.~~

17. (Currently Amended) A method according to claim 16, wherein each of said peptides a, b, and c, ~~and d~~ consists of up to 50 amino acid residues.

18. (Previously Presented) A method according to claim 16, wherein all of the amino acid residues of said peptides a, b, c, and d are in the L form.

19. (Previously Presented) A method according to claim 16, wherein at least two of said peptides a, b, c, and d are linked together through an inter- or intra-molecular bond that is a -S-(CH₂)_p-S-bridge or a -(CH₂)_p - bridge wherein p = 1-8 optionally intervened by one or more heteroatoms selected from the group consisting of O, N and S.

20. (Previously Presented) A method according to claim 16, wherein the combination of peptides is administered with one or more cytokines.

21. (Previously Presented) A method according to claim 16, wherein said peptides a, b, c, and d are administered while dissolved in saline water and are administered in combination with a granulocyte macrophage growth factor.

22. (Previously Presented) A method according to claim 16, wherein the combination of peptides is administered with an adjuvant selected from the group consisting of Monophosphoryl Lipid A, Freund's complete or incomplete adjuvant, and aluminum hydroxide.

23. (Previously Presented) A method according to claim 16, wherein the ratio of peptides a/b/c/d in the combination is 1/1/1/1.

24. (Previously Presented) A method according to claim 16, wherein the combination of peptides is administered in the form of a dosage unit that provides 1 μ g to 1 mg of each of said peptides a, b, c, and d per kg of bodyweight of the human.

25. (Previously Presented) The method according to claim 24, wherein the administration of said dosage unit is performed at least three times.

26. (Previously Presented) The method according to claim 25, wherein said dosage unit provides 2 μ g to 0.15 mg of each of said peptides a, b, c, and d per kg of bodyweight of the human.

27. (Previously Presented) A method according to claim 26, wherein the dosage unit is in the form of a sterile sodium chloride solution and the administration is by injection.

28. (Previously Presented) A method according to any one of claims 16-27, wherein said peptide a is SEQ ID NO. 3.

29. (Previously Presented) A method according to any one of claims 16-27, wherein said peptide b is SEQ ID NO. 6.

30. (Previously Presented) A method according to any one of claims 16-27, wherein said peptide c is SEQ ID NO. 11.

31. (Previously Presented) A method according to any one of claims 16-27, wherein said peptide d is SEQ ID NO. 18.

32. (Previously Presented) A method according to any one of claims 16-27, wherein said peptide a is SEQ ID NO. 3, said peptide b is SEQ ID NO. 6, said peptide c is SEQ ID NO. 11, and said peptide d is SEQ ID No. 18.

33. (Currently Amended) A method of stimulating the immune system of a human to produce an HIV-1 immune response, comprising administering to the human a pharmaceutical composition comprising at least one peptide selected from the group

consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ

ID NO: 20 that comprises the sequence Xaa₁Xaa₂Ile Ile Xaa₃Xaa₄Xaa₅Xaa₆Xaa₇Xaa₈Xaa₉Leu

Xaa₁₁[Gly]_n[Arg]_mXaa₁₂Xaa₁₃Xaa₁₄Xaa₁₅Xaa₁₆Xaa₁₇Xaa₁₈Xaa₁₉Xaa₂₀Xaa₂₁Xaa₂₂

Xaa₂₃Xaa₂₄Xaa₂₅(SEQ ID NO: 15)

_____wherein Xaa in position 1 is Pro, Lys, Arg or none;

_____Xaa in position 2 is Glu, Arg, Phe or Lys;

_____Xaa in position 5 is Pro or Thr;

_____Xaa in position 6 is Met, Thr or Nle;

_____Xaa in position 7 is Phe or Leu;

_____Xaa in position 8 is Ser, Thr, Ala or Met;

_____Xaa in position 9 is Ala, Glu or Leu;

_____Xaa in position 11 is Ser or none;

_____Xaa in position 12, is Ala, Arg or none;

_____Xaa in position 13 is Ile, Leu or none;

_____Xaa in position 14 is Ser, Ala, Leu or none;

_____Xaa in position 15 is Tyr, Glu or Asp;

_____Xaa in position 16 is Gly or Asp;

_____Xaa in position 17 is Ala or Leu;

_____Xaa in position 18 is Thr, Ile, Val, Leu or Asn;

_____Xaa in position 19 is Pro, Thr or Ser;

_____Xaa in position 20 is Tyr, Phe, Nle, His or Gln;

_____Xaa in position 21 is Asp, Asn, Leu or Ala;

_____Xaa in position 22 is Leu, Ile, Val or Asn;

~~_____ Xaa in position 23 is Asn, Tyr, Cys or Gly;~~
~~_____ Xaa in position 24 is Thr, Met, Ile, Ala, Val or none, and~~
~~_____ Xaa in position 25 is Gly or none, and~~
~~_____ wherein n = 1, 2 or 3, and m = 0, 1, 2 or 3, and~~
a pharmaceutically acceptable diluent.

34. (Cancelled).

35. (Currently Amended) The method according to claim 33 ~~34~~, wherein all of the amino acid residues of said peptide are in the L form.

36. (Cancelled).

37. (Currently Amended) The method according to claim 33 ~~34~~, wherein the pharmaceutical composition is administered in conjunction with the administration of one or more cytokines.

38. (Currently Amended) The method according to claim 33 ~~34~~, wherein said peptide is dissolved in saline water and the pharmaceutical composition is administered in conjunction with a granulocyte macrophage growth factor.

39. (Currently Amended) The method according to claim 33 ~~34~~, wherein the pharmaceutical composition comprises an adjuvant selected from the group consisting

of Monophosphoryl Lipid A, Freund's complete or incomplete adjuvant, and aluminum hydroxide.

40. (Currently Amended) The method according to claim ~~33~~ 34, wherein the pharmaceutical composition is administered in the form of a dosage unit that provides 1 µg to 1 mg of said peptide per kg of bodyweight of the human.

41. (Previously Presented) The method according to claim 40, wherein the administration of said dosage unit is performed at least three times.

42. (Previously Presented) The method according to claim 41, wherein said dosage unit provides 2 µg to 0.15 mg of said peptide per kg of bodyweight of the human.

43. (Previously Presented) The method according to claim 42, wherein the pharmaceutical composition is in the form of a sterile sodium chloride solution and the administration is by injection.

44. (Currently Amended) The method according to any one of claims 33 or 37-43, wherein said at least one peptide is ~~consists of~~ SEQ ID NO. 18.

45. (Currently Amended) An isolated peptide selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ

ID NO: 20 that comprises the sequence ~~Xaa₁-Xaa₂-Ile-Ile-Xaa₅-Xaa₆-Xaa₇-Xaa₈-Xaa₉-Leu~~
~~Xaa₁₁-[Gly]_n-[Arg]_m-Xaa₁₂-Xaa₁₃-Xaa₁₄-Xaa₁₅-Xaa₁₆-Xaa₁₇-Xaa₁₈-Xaa₁₉-Xaa₂₀-Xaa₂₁-Xaa₂₂~~
~~Xaa₂₃-Xaa₂₄-Xaa₂₅ (SEQ ID NO: 15)~~

~~_____ wherein Xaa in position 1 is Pro, Lys, Arg or none;~~

~~_____ Xaa in position 2 is Glu, Arg, Phe or Lys;~~

~~_____ Xaa in position 5 is Pro or Thr;~~

~~_____ Xaa in position 6 is Met, Thr or Nle;~~

~~_____ Xaa in position 7 is Phe or Leu;~~

~~_____ Xaa in position 8 is Ser, Thr, Ala or Met;~~

~~_____ Xaa in position 9 is Ala, Glu or Leu;~~

~~_____ Xaa in position 11 is Ser or none;~~

~~_____ Xaa in position 12, is Ala, Arg or none;~~

~~_____ Xaa in position 13 is Ile, Leu or none;~~

~~_____ Xaa in position 14 is Ser, Ala, Leu or none;~~

~~_____ Xaa in position 15 is Tyr, Glu or Asp;~~

~~_____ Xaa in position 16 is Gly or Asp;~~

~~_____ Xaa in position 17 is Ala or Leu;~~

~~_____ Xaa in position 18 is Thr, Ile, Val, Leu or Asn;~~

~~_____ Xaa in position 19 is Pro, Thr or Ser;~~

~~_____ Xaa in position 20 is Tyr, Phe, Nle, His or Gln;~~

~~_____ Xaa in position 21 is Asp, Asn, Leu or Ala;~~

~~_____ Xaa in position 22 is Leu, Ile, Val or Asn;~~

~~_____ Xaa in position 23 is Asn, Tyr, Cys or Gly;~~

~~_____ Xaa in position 24 is Thr, Met, Ile, Ala, Val or none, and~~

~~_____ Xaa in position 25 is Gly or none, and~~

~~_____ wherein n = 1, 2 or 3, and m = 0, 1, 2 or 3.~~

46. (Cancelled).

47. (Currently Amended) The isolated peptide according to claim ~~45~~ 46, wherein all of the amino acid residues of said peptide are in the L form.

48. (Cancelled).

49. (Currently Amended) The peptide of claim 45, wherein the peptide is ~~consists of~~ SEQ ID NO. 18.

50. (Previously Presented) The peptide of claim 49, wherein the terminal ends of the peptide are selected from the group consisting of free carboxyl groups, amino groups, and amides.

51. (Previously Presented) The peptide of claim 49, wherein the peptide is immobilized to a solid support.

52. (Previously Presented) The peptide of claim 50, wherein the peptide is immobilized to a solid support.